Evidence map›Paper›PMID 42169999›Full record

ArticleJournal of human immunity2026

Polyclonal evolution of lymphoproliferative disorders in XLP1.

Dan Tomomasa, Akira Nishimura, Kenichi Yoshida, Yui Namikawa, Doo Ri Kim, Naoki Sakata, Kenichi Sakamoto, Takashi Taga, Yuta Sakai, Yasuhiro Ikawa and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Dan Tomomasa *Department of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0009-0003-3236-5098
Akira Nishimura *Department of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9127-807X
Kenichi YoshidaDivision of Cancer Evolution, National Cancer Center Research Institute, Tokyo, Japan.ORCID https://orcid.org/0000-0003-4612-2778
Yui NamikawaDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0009-0005-1550-7175
Doo Ri KimDepartment of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-5233-4043
Naoki SakataDepartment of Pediatrics, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.ORCID https://orcid.org/0000-0003-3522-3995
Kenichi SakamotoDepartment of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.ORCID https://orcid.org/0000-0003-1499-538X
Takashi TagaDepartment of Pediatrics, Shiga University of Medical Science, Shiga, Japan.ORCID https://orcid.org/0000-0003-0525-4766
Yuta SakaiDepartment of Pediatrics School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.ORCID https://orcid.org/0009-0001-3649-9443
Yasuhiro IkawaDepartment of Pediatrics School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.ORCID https://orcid.org/0000-0001-7204-1766
Toshiaki IshidaDepartment of Hematology and Oncology, Kobe Children's Hospital, Kobe, Japan.ORCID https://orcid.org/0000-0002-8327-1089
Areum ShinDepartment of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-3341-0447
Keon Hee YooDepartment of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-5980-7912
Yae-Jean KimDepartment of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8367-3424
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-7778-5374
Akihiro HoshinoDepartment of Child Health and Development, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4392-0988
Tomohiro MorioDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9259-1025
Masatoshi TakagiDepartment of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7580-9184
Hirokazu KaneganeDepartment of Child Health and Development, Institute of Science Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0002-8696-9378

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-linked lymphoproliferative syndrome type 1 (XLP1) is an inborn error of immunity caused by pathogenic variants in

Identifiers

PMID42169999
PMCPMC13177645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.